Khiron Life Sciences Looks To Acquire PharmaDrug’s German Subsidiary For $2.0 Million

Khiron Life Sciences Corp. (TSXV: KHRN) announced today the plan to acquire Pharmadrug GmbH, a German cannabis subsidiary of PharmaDrug Inc. (CSE: PHRX). The total consideration for the transaction is estimated at $2.0 million.

“This acquisition will provide us with a European manufacturing and distribution centre for cannabinoid-based medicines with EU-GMP certification,” said Khiron Europe President Franziska Katterbach.

The transaction will partially be satisfied with the issuance of 5.5 million Khiron common shares at $0.16 per share. The Canadian cannabis firm will also issue a non-interest-bearing promissory note for $1.1 million which will be payable within one year after closing either via cash or company shares.

The companies expect the acquisition to close in July 2022, subject to regulatory approvals and customary closing conditions.

The German subsidiary carries a Schedule I European Union narcotics license, an EU-GMP certification, and an EU-GDP certification–fulfilling the region’s standards in manufacturing and distributing pharmaceutical products.

The acquisition plans follow Khiron’s first foray into the European market back in November 2021 through the opening of its first Zerenia Clinics UK in London.

Khiron Life Sciences last traded at $0.17 on the TSX Venture.


Information for this briefing was found via Sedar and the companies mentioned. The author has no securities or affiliations related to this organization. Not a recommendation to buy or sell. Always do additional research and consult a professional before purchasing a security. The author holds no licenses.

Video Articles

Aznalcóllar Corruption Case Nears Conclusion | David Gower – Emerita Resources

Why Precious Metals Crashed on Trump’s Trade Deals? | Jesse Day

Big Gold Miners Don’t Trust $3,300 Gold, Do They See a Crash Ahead? | Rob McEwen

Recommended

NexGen Energy Receives Approval For Site Expansion At Rook I Project

ESGold Sees Installation Of Humphrey Spirals Completed At Montauban

Related News

PharmaDrug Joint Venture Receives Approval For Phase 1 Clinical Trial

Pharmadrug Inc (CSE: PHRX) has received approval for its majority owned joint venture, Sairiyo Therapeutics,...
Monday, August 19, 2024, 09:08:46 AM

Khiron Receives National Strategic Project Status From Colombian Government

This morning Khiron Life Sciences Corp (TSXV: KHRN) announced they received the status of National...

Tuesday, September 22, 2020, 09:43:55 AM

Khiron Life Sciences Conducts Bought Deal Financing For Gross Proceeds Of $10.0 Million

Khiron Life Sciences (TSXV: KHRN) announced that it is conducting at $10.0 bought deal private...

Monday, November 9, 2020, 08:43:24 AM

Drug Trade: The Three Basic Cannabis Health Company Archetypes

The popular belief that cannabis will work its way further into mainstream culture and further...

Saturday, December 21, 2019, 08:00:00 AM

Khiron Signs Exclusive Partnership with Rappi, The Amazon Of South America

Khiron Life Sciences (TSXV: KHRN) this morning announced the significant development of establishing an exclusive...

Friday, September 4, 2020, 08:17:02 AM